ArticleCell host & microbe2023
Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants.
Open access · hybridAbstract read
In one paragraph
Article in Cell host & microbe, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- AZD5582 robustly reactivates latently infected cells and clears the majority of those reactivated from the SIV reservoir.bioRxiv : the preprint server for biology · 2026Article
- Initiation of Long-Acting Antiretroviral Combinations Achieve Sustained Virologic Remission in Early-Life SIV Infection.Research square · 2026Article
- Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.Nature microbiology · 2026Article
- Post-treatment SIV control is associated with specific features of viral persistence before and after treatment interruption.Nature communications · 2026Article
- Dynamics of natural and pharmacologic control of an SIV variant with an envelope trafficking defect.The Journal of experimental medicine · 2026Article
- Clonal heterogeneity and antigenic stimulation shape persistence of the latent reservoir of HIV.PLoS computational biology · 2025Article
- SIV proviruses seeded later in infection are harbored in short-lived CD4Cell reports · 2025Article
- Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques.Infectious disease reports · 2025Review
- SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity.Nature communications · 2024Article
- No evidence for ongoing replication on ART in SIV-infected macaques.Nature communications · 2024Article
- Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir.PLoS pathogens · 2024Article
- Quantitative and Qualitative Distinctions between HIV-1 and SIV Reservoirs: Implications for HIV-1 Cure-Related Studies.Viruses · 2024Review
- CD4+ T cells with latent HIV-1 have reduced proliferative responses to T cell receptor stimulation.The Journal of experimental medicine · 2024Article
- The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time.Journal of virology · 2024Article
- TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo.Nature communications · 2024Article
- Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8Nature communications · 2024Article
- Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy.The Journal of clinical investigation · 2023Article
- Antigen specificities of HIV-infected cells: A role in infection and persistence?Journal of virus eradication · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Emily J FrayDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: efray1@jhmi.edu.
Fengting WuDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Francesco R SimonettiDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Carolin ZitzmannLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Narmada SambaturuLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Carmen Molina-ParisLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Alexandra M BenderDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Po-Ting LiuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
John D VenturaCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Roger W WisemanWisconsin National Primate Research Center, Madison, WI 53715, USA.
David H O'ConnorWisconsin National Primate Research Center, Madison, WI 53715, USA.
Romas GeleziunasGilead Sciences, Foster City, CA 94404, USA.
Thomas LeitnerLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Ruy M RibeiroLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Alan S PerelsonLos Alamos National Laboratory, Los Alamos, NM 87545, USA.
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Janet D SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, Baltimore, MD 21205, USA. Electronic address: rsiliciano@jhmi.edu.
Los Alamos National Laboratory · USJohns Hopkins Medicine · USBeth Israel Deaconess Medical Center · USJohns Hopkins University · USGilead Sciences (United States) · US
Funding
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7MConsortia for Innovative AIDS Research in Nonhuman PrimatesUM1AI124377 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., PICKER, LOUIS J. · 2016 to 2021
$53.0MBEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7MReversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0MI4C 2.0: Immunotherapy for CureUM1AI164556 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Dan H. Barouch, John W Mellors · 2021 to 2026
$28.0MProject 2U19AI128751 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2018 to 2022
$14.0MReconstructing HIV Epidemics from HIV PhylogeneticsR01AI087520 · NIAID · TRIAD NATIONAL SECURITY, LLC · PI Thomas K. Leitner · 2010 to 2026
$11.2MUnderstanding reservoir dynamics through analysis of viral decay processesP01AI169615 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ROBERT F SILICIANO · 2022 to 2026
$9.5MViral dynamics of rebound and control following early treatment of HIV/SIVP01AI131365 · NIAID · BOSTON COLLEGE · PI WHITNEY, JAMES BURTON · 2017 to 2021
$7.5MModeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0MSingle-Cell Analysis of the HIV/SIV ReservoirR01AI149670 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H., SHALEK, ALEX K · 2020 to 2024
$4.6MImmune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7MNIAID NIH HHS P01 AI131365NIAID NIH HHS P01 AI169615NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI087520NIAID NIH HHS R01 AI149670NIAID NIH HHS U19 AI128751NIAID NIH HHS UM1 AI124377NIAID NIH HHS UM1 AI164556NIAID NIH HHS UM1 AI164561NIAID NIH HHS UM1 AI164570NIH HHS DP5 OD031834NIH HHS P51 OD011106NIH HHS R01 OD011095
Abstract
The decay kinetics of HIV-1-infected cells are critical to understand virus persistence. We evaluated the frequency of simian immunodeficiency virus (SIV)-infected cells for 4 years of antiretroviral therapy (ART). The intact proviral DNA assay (IPDA) and an assay for hypermutated proviruses revealed short- and long-term infected cell dynamics in macaques starting ART ∼1 year after infection. Intact SIV genomes in circulating CD4
Indexed as
HIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsAnti-Retroviral AgentsCD4-Positive T-LymphocytesMacaca mulattaProvirusesViral LoadAnti-Retroviral Agentsclonal expansiondecaydefective proviruslatent reservoirSIV
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.